Clinical Trial

Establishing Radiolabelled PSMA as a Target for Glioma Treatment

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
A study is being performed to observe whether a novel type of brain imaging using a technique called PET-MRI may provide useful information in the 'mapping' of adult primary brain tumours. It employs a radiolabelled molecule targeting a particular molecule called PSMA which is hypothesised to be a marker of aggression in primary brain tumours. 'Mapping' of the concentration and distribution of this molecule within brain tumours via PET-MRI may provide vital clinical information regarding the extent and timing of treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-02-21.
Trial Details
NCT Number NCT05263466
Lead Sponsor King's College Hospital NHS Trust
Collaborators: King's College London
Conditions Glioma, Malignant
Enrollment 30 participants
Start Date 2022-08-01
Primary Completion 2027-05-01 (estimated)
Study Completion 2027-05-01 (estimated)
Updated on ClinicalTrials.gov 2022-06-10